Search

Your search keyword '"Oberlin, O"' showing total 599 results
Start Over Author "Oberlin, O"
599 results on '"Oberlin, O"'

1. Suture versus open mesh repair for small umbilical hernia: Results of a propensity-matched cohort study

Author

Antor, M., Beck, M., Barrat, C., Berney, C., Binot, D., Bousquet, J., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Chollet, J.-M., Cossa, J.-P., Dabrowski, A., Delaunay, T., Démaret, S., Drissi, F., Demian, H., Dubuisson, V., Dugue, T., Fromont, G., Gillion, J.-F., Jacquin, C., Jurczak, F., Khalil, H., Launay-Savary, M., Lepère, M., Lépront, D., Longeville, J.H., Le Toux, N., Loriau, J., Magne, E., Ngo, P., Oberlin, O., Passot, G., Pavis d’Escurac, X., Putinier, J.B., Renard, Y., Romain, B., Soler, M., Roos, S., Thillois, J.-M., Tiry, P., Vu, P., Verhaeghe, R., Warlaumont, M., Zaranis, C., Frey, Samuel, Beauvais, Adrien, Soler, Marc, Beck, Mathieu, Dugué, Timothée, Pavis d’Escurac, Xavier, Dabrowski, André, Jurczak, Florent, and Gillion, Jean-François

Published
2023
Full Text
View/download PDF

2. Functional outcomes in symptomatic versus asymptomatic patients undergoing incisional hernia repair: Replacing one problem with another? A prospective cohort study in 1312 patients

Author

Abet, E., Ain, J.-F., Arnalsteen, L., Baraket, O., Beck, M., Bellouard, A., Benizri, E., Berney, C., Bilem, D., Binot, D., Blanc, B., Blazquez, D., Bonan, A., Boukortt, T., Brehant, O., Cas, O., Champault-Fezais, A., Chau, A., Chollet, J.-M., Constantin, M., Cossa, J.-P., Dabrowski, A., David, A., Demaret, S., Dubuisson, V., Dugue, T., El Nakadi, I., Faure, J.-P., Frileux, P., Fromont, G., Gadiri, N., Gillion, J.-F., Glehen, O., Hennequin, S., Isambert, M., Jurczak, F., Khalil, H., Lamblin, A., Largenton, C., Lavy, M., Lepère, M., Le Toux, N., Magne, E., Manfredelli, S., Mariette, C., Marion, Y., Mercoli, H.-A., Mesli Smain, N., Moszkowicz, D., Najim, M., Oberlin, O., Odet, E., Ortega Deballon, P., Pavis d’Escurac, X., Pichot Delahaye, V., Putinier, J.B., Regimbeau, J.M., Renard, Y., Romain, B., Rouquie, D., Soler, M., Soufron, J., Roos, S., Thillois, J.-M., Tiry, P., Vauchaussade De Chaumont, A., Vinatier, E., Vu, P., Verhaeghe, R., Zaranis, C., Zeineb, M., de Smet, Gijs H.J., Sneiders, Dimitri, Yurtkap, Yagmur, Menon, Anand G., Jeekel, Johannes, Kleinrensink, Gert-Jan, Lange, Johan F., and Gillion, Jean-François

Published
2020
Full Text
View/download PDF

4. External Validation of the European Hernia Society Classification for Postoperative Complications after Incisional Hernia Repair: A Cohort Study of 2,191 Patients

Author

Ain, J.-F., Beck, M., Barrat, C., Berney, C., Berrod, J.-L., Binot, D., Boudet, M.-J., Bousquet, J., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Cardin, J.-L., Chollet, J.-M., Cossa, J.-P., Dabrowski, A., Démaret, S., Drissi, F., Durou, J., Dugue, T., Faure, J.-P., Framery, D., Fromont, G., Gainant, A., Gauduchon, L., Genser, L., Gillion, J.-F., Guillaud, A., Jacquin, C., Jurczak, F., Khalil, H., Lacroix, A., Ledaguenel, P., Lepère, M., Lépront, D., Letoux, N., Loriau, J., Magne, E., Ngo, P., Oberlin, O., Paterne, D., Pavis d'Escurac, X., Potiron, L., Renard, Y., Soler, M., Rignier, P., Roos, S., Thillois, J.-M., Tiry, P., Verhaeghe, R., Vu, P., Zaranis, C., Kroese, Leonard F., Kleinrensink, Gert-Jan, Lange, Johan F., and Gillion, Jean-Francois

Published
2018
Full Text
View/download PDF

6. Suture versus open mesh repair for small umbilical hernia: Results of a propensity-matched cohort study

Author

Frey, Samuel, primary, Beauvais, Adrien, additional, Soler, Marc, additional, Beck, Mathieu, additional, Dugué, Timothée, additional, Pavis d’Escurac, Xavier, additional, Dabrowski, André, additional, Jurczak, Florent, additional, Gillion, Jean-François, additional, Antor, M., additional, Beck, M., additional, Barrat, C., additional, Berney, C., additional, Binot, D., additional, Bousquet, J., additional, Blazquez, D., additional, Bonan, A., additional, Cas, O., additional, Champault-Fezais, A., additional, Chastan, P., additional, Chollet, J.-M., additional, Cossa, J.-P., additional, Dabrowski, A., additional, Delaunay, T., additional, Démaret, S., additional, Drissi, F., additional, Demian, H., additional, Dubuisson, V., additional, Dugue, T., additional, Fromont, G., additional, Gillion, J.-F., additional, Jacquin, C., additional, Jurczak, F., additional, Khalil, H., additional, Launay-Savary, M., additional, Lepère, M., additional, Lépront, D., additional, Longeville, J.H., additional, Le Toux, N., additional, Loriau, J., additional, Magne, E., additional, Ngo, P., additional, Oberlin, O., additional, Passot, G., additional, Pavis d’Escurac, X., additional, Putinier, J.B., additional, Renard, Y., additional, Romain, B., additional, Soler, M., additional, Roos, S., additional, Thillois, J.-M., additional, Tiry, P., additional, Vu, P., additional, Verhaeghe, R., additional, Warlaumont, M., additional, and Zaranis, C., additional

Published
2023
Full Text
View/download PDF

17. Hodgkin’s Disease

Author

Donaldson, S. S., Oberlin, O., Bamberg, Michael, editor, Voûte, P. A., editor, Barrett, Ann, editor, and Lemerle, Jean, editor

Published
1992
Full Text
View/download PDF

18. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

Author

Bellera, C. A., Penel, N., Ouali, M., Bonvalot, S., Casali, P. G., Nielsen, O. S., Delannes, M., Litière, S., Bonnetain, F., Dabakuyo, T. S., Benjamin, R. S., Blay, J.-Y., Bui, B. N., Collin, F., Delaney, T. F., Duffaud, F., Filleron, T., Fiore, M., Gelderblom, H., George, S., Grimer, R., Grosclaude, P., Gronchi, A., Haas, R., Hohenberger, P., Issels, R., Italiano, A., Jooste, V., Krarup-Hansen, A., Le Péchoux, C., Mussi, C., Oberlin, O., Patel, S., Piperno-Neumann, S., Raut, C., Ray-Coquard, I., Rutkowski, P., Schuetze, S., Sleijfer, S., Stoeckle, E., Van Glabbeke, M., Woll, P., Gourgou-Bourgade, S., and Mathoulin-Pélissier, S.

Published
2015
Full Text
View/download PDF

26. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008

Author

Whelan, J., Deley, M.C. le, Dirksen, U., Teuff, G. le, Brennan, B., Gaspar, N., Hawkins, D.S., Amler, S., Bauer, S., Bielack, S., Blay, J.Y., Burdach, S., Castex, M.P., Dilloo, D., Eggert, A., Gelderblom, H., Gentet, J.C., Hartmann, W., Hassenpflug, W.A., Hjorth, L., Jimenez, M., Klingebiel, T., Kontny, U., Kruseova, J., Ladenstein, R., Laurence, V., Lervat, C., Marec-Berard, P., Marreaud, S., Michon, J., Morland, B., Paulussen, M., Ranft, A., Reichardt, P., Berg, H. van den, Wheatley, K., Judson, I., Lewis, I., Craft, A., Juergens, H., Oberlin, O., Euro- E W I N G 99 Investigator, EWING-2008 Investigator, Paediatric Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
0301 basic medicine, Melphalan, Cancer Research, medicine.medical_specialty, Vincristine, medicine.medical_treatment, Medizin, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Original Reports, Medicine, Etoposide, Chemotherapy, Ifosfamide, business.industry, Hazard ratio, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Sarcoma, business, Busulfan, medicine.drug
Abstract

Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine, dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger than 50 years of age with poor histologic response (≥ 10% viable cells) after receiving vincristine, ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis ≥ 200 mL if unresected, or initially resected, or resected after radiotherapy. A 15% improvement in 3-year event-free survival (EFS) was sought (hazard ratio [HR], 0.60). Results Between 2000 and 2015, 240 patients classified as high risk (median age, 17.1 years) were randomly assigned to VAI (n = 118) or BuMel (n = 122). Seventy-eight percent entered the trial because of poor histologic response after chemotherapy alone. Median follow-up was 7.8 years. In an intent-to-treat analysis, the risk of event was significantly decreased by BuMel compared with VAI: HR, 0.64 (95% CI, 0.43 to 0.95; P = .026); 3- and 8-year EFS were, respectively, 69.0% (95% CI, 60.2% to 76.6%) versus 56.7% (95% CI, 47.6% to 65.4%) and 60.7% (95% CI, 51.1% to 69.6%) versus 47.1% (95% CI, 37.7% to 56.8%). Overall survival (OS) also favored BuMel: HR, 0.63 (95% CI, 0.41 to 0.95; P = .028); 3- and 8-year OS were, respectively, 78.0% (95% CI, 69.6% to 84.5%) versus 72.2% (95% CI, 63.3% to 79.6%) and 64.5% (95% CI, 54.4% to 73.5%) versus 55.6% (95% CI, 45.8% to 65.1%). Results were consistent in the sensitivity analysis. Two patients died as a result of BuMel-related toxicity, one after standard chemotherapy. Significantly more BuMel patients experienced severe acute toxicities from this course of chemotherapy compared with multiple VAI courses. Conclusion BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction in localized ES with predefined high-risk factors. For this group of patients, BuMel may be an important addition to the standard of care.

Published
2018
Full Text
View/download PDF

27. Functional outcomes in symptomatic versus asymptomatic patients undergoing incisional hernia repair: Replacing one problem with another? A prospective cohort study in 1312 patients

Author

Smet, G.H.J. de, Sneiders, D. (Dimitri), Yurtkap, Y. (Yağmur), Menon, A.G. (Anand), Jeekel, J. (Hans), Kleinrensink, G.J. (Gert Jan), Lange, J.F. (Johan), Gillion, J.-F. (Jean-François), Abet, E. (E.), Ain, J.-F. (J. F.), Arnalsteen, L. (L.), Baraket, O. (O.), Beck, M. (M.), Bellouard, A. (A.), Benizri, E. (E.), Berney, C. (C.), Bilem, D. (D.), Binot, D. (D.), Blanc, B. (B.), Blazquez, D. (D.), Bonan, A. (A.), Boukortt, T. (T.), Brehant, O. (O.), Cas, O. (O.), Champault-Fezais, A. (A.), Chau, A. (A.), Chollet, J.-M. (J. M.), Constantin, M. (M.), Cossa, J.-P. (J. P.), Dabrowski, A. (A.), David, A. (A.), Demaret, S. (S.), Dubuisson, V. (V.), Dugue, T. (T.), El Nakadi, I., Faure, J.-P. (J. P.), Frileux, P. (P.), Fromont, G. (G.), Gadiri, N. (N.), Gillion, J.F. (Jean-Francois), Glehen, O. (O.), Hennequin, S. (S.), Isambert, M. (M.), Jurczak, F. (F.), Khalil, H. (H.), Lamblin, A. (A.), Largenton, C. (C.), Lavy, M. (M.), Lepère, M. (M.), Le Toux, N. (N.), Magne, E. (E.), Manfredelli, S. (S.), Mariette, C. (Christophe), Marion, Y. (Y.), Mercoli, H.-A. (H. A.), Mesli Smain, N. (N.), Moszkowicz, D. (D.), Najim, M. (M.), Oberlin, O. (O.), Odet, E. (E.), Ortega Deballon, P. (P.), Pavis d'Escurac, X. (X.), Pichot Delahaye, V. (V.), Putinier, J.B. (J. B.), Regimbeau, J.M. (J. M.), Renard, Y. (Y.), Romain, B. (B.), Rouquie, D. (D.), Soler, M. (M.), Soufron, J. (J.), Roos, S. (S.), Thillois, J.-M. (J. M.), Tiry, P. (P.), Vauchaussade De Chaumont, A. (A.), Vinatier, E. (E.), Vu, P. (P.), Verhaeghe, R. (R.), Zaranis, C. (C.), Zeineb, M. (M.), Smet, G.H.J. de, Sneiders, D. (Dimitri), Yurtkap, Y. (Yağmur), Menon, A.G. (Anand), Jeekel, J. (Hans), Kleinrensink, G.J. (Gert Jan), Lange, J.F. (Johan), Gillion, J.-F. (Jean-François), Abet, E. (E.), Ain, J.-F. (J. F.), Arnalsteen, L. (L.), Baraket, O. (O.), Beck, M. (M.), Bellouard, A. (A.), Benizri, E. (E.), Berney, C. (C.), Bilem, D. (D.), Binot, D. (D.), Blanc, B. (B.), Blazquez, D. (D.), Bonan, A. (A.), Boukortt, T. (T.), Brehant, O. (O.), Cas, O. (O.), Champault-Fezais, A. (A.), Chau, A. (A.), Chollet, J.-M. (J. M.), Constantin, M. (M.), Cossa, J.-P. (J. P.), Dabrowski, A. (A.), David, A. (A.), Demaret, S. (S.), Dubuisson, V. (V.), Dugue, T. (T.), El Nakadi, I., Faure, J.-P. (J. P.), Frileux, P. (P.), Fromont, G. (G.), Gadiri, N. (N.), Gillion, J.F. (Jean-Francois), Glehen, O. (O.), Hennequin, S. (S.), Isambert, M. (M.), Jurczak, F. (F.), Khalil, H. (H.), Lamblin, A. (A.), Largenton, C. (C.), Lavy, M. (M.), Lepère, M. (M.), Le Toux, N. (N.), Magne, E. (E.), Manfredelli, S. (S.), Mariette, C. (Christophe), Marion, Y. (Y.), Mercoli, H.-A. (H. A.), Mesli Smain, N. (N.), Moszkowicz, D. (D.), Najim, M. (M.), Oberlin, O. (O.), Odet, E. (E.), Ortega Deballon, P. (P.), Pavis d'Escurac, X. (X.), Pichot Delahaye, V. (V.), Putinier, J.B. (J. B.), Regimbeau, J.M. (J. M.), Renard, Y. (Y.), Romain, B. (B.), Rouquie, D. (D.), Soler, M. (M.), Soufron, J. (J.), Roos, S. (S.), Thillois, J.-M. (J. M.), Tiry, P. (P.), Vauchaussade De Chaumont, A. (A.), Vinatier, E. (E.), Vu, P. (P.), Verhaeghe, R. (R.), Zaranis, C. (C.), and Zeineb, M. (M.)

Abstract

Background: Incisional hernias can be associated with pain or discomfort. Surgical repair especially mesh reinforcement, may likewise induce pain. The primary objective was to assess the incidence of pain after hernia repair in patients with and without pre-operative pain or discomfort. The secondary objectives were to determine the preferred mesh type, mesh location and surgical technique in minimizing postoperative pain or discomfort. Materials and methods: A registry-based prospective cohort study was performed, including patients undergoing incisional hernia repair between September 2011 and May 2019. Patients with a minimum follow-up of 3–6 months were included. The incidence of hernia related pain and discomfort was recorded perioperatively. Results: A total of 1312 patients were included. Pre-operatively, 1091 (83%) patients reported pain or discomfort. After hernia repair, 961 (73%) patients did not report pain or discomfort (mean follow-up = 11.1 months). Of the pre-operative asymptomatic patients (n = 221), 44 (20%, moderate or severe pain: n = 14, 32%) reported pain or discomfort after mean follow-up of 10.5 months. Of those patients initially reporting pain or discomfort (n = 1091), 307 (28%, moderate or severe pain: n = 80, 26%) still reported pain or discomfort after a mean follow-up of 11.3 months postoperatively. Conclusion: In symptomatic incisional hernia patients, hernia related complaints may be resolved in the majority of cases undergoing surgical repair. In asymptomatic incisional hernia patients, pain or discomfort may be induced in a considerable number of patients due to surgical repair and one should be aware if this postoperative complication.

Published
2020
Full Text
View/download PDF

31. Functional outcomes in symptomatic versus asymptomatic patients undergoing incisional hernia repair: Replacing one problem with another? A prospective cohort study in 1312 patients

Author

de Smet, Gijs H.J., primary, Sneiders, Dimitri, additional, Yurtkap, Yagmur, additional, Menon, Anand G., additional, Jeekel, Johannes, additional, Kleinrensink, Gert-Jan, additional, Lange, Johan F., additional, Gillion, Jean-François, additional, Abet, E., additional, Ain, J.-F., additional, Arnalsteen, L., additional, Baraket, O., additional, Beck, M., additional, Bellouard, A., additional, Benizri, E., additional, Berney, C., additional, Bilem, D., additional, Binot, D., additional, Blanc, B., additional, Blazquez, D., additional, Bonan, A., additional, Boukortt, T., additional, Brehant, O., additional, Cas, O., additional, Champault-Fezais, A., additional, Chau, A., additional, Chollet, J.-M., additional, Constantin, M., additional, Cossa, J.-P., additional, Dabrowski, A., additional, David, A., additional, Demaret, S., additional, Dubuisson, V., additional, Dugue, T., additional, El Nakadi, I., additional, Faure, J.-P., additional, Frileux, P., additional, Fromont, G., additional, Gadiri, N., additional, Gillion, J.-F., additional, Glehen, O., additional, Hennequin, S., additional, Isambert, M., additional, Jurczak, F., additional, Khalil, H., additional, Lamblin, A., additional, Largenton, C., additional, Lavy, M., additional, Lepère, M., additional, Le Toux, N., additional, Magne, E., additional, Manfredelli, S., additional, Mariette, C., additional, Marion, Y., additional, Mercoli, H.-A., additional, Mesli Smain, N., additional, Moszkowicz, D., additional, Najim, M., additional, Oberlin, O., additional, Odet, E., additional, Ortega Deballon, P., additional, Pavis d’Escurac, X., additional, Pichot Delahaye, V., additional, Putinier, J.B., additional, Regimbeau, J.M., additional, Renard, Y., additional, Romain, B., additional, Rouquie, D., additional, Soler, M., additional, Soufron, J., additional, Roos, S., additional, Thillois, J.-M., additional, Tiry, P., additional, Vauchaussade De Chaumont, A., additional, Vinatier, E., additional, Vu, P., additional, Verhaeghe, R., additional, Zaranis, C., additional, and Zeineb, M., additional

Published
2020
Full Text
View/download PDF

48. Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups

Author

Minard-Colin, V, Walterhouse, D, Bisogno, G, Martelli, H, Anderson, J, Rodeberg, Da, Ferrari, A, Jenney, M, Wolden, S, De Salvo, G, Arndt, C, Merks, Jhm, Gallego, S, Schwob, D, Haie-Meder, C, Bergeron, C, Stevens, Mcg, Oberlin, O, Hawkins, D, International Society of Pediatric Oncology Sarcoma Committee, the Children's Oncology Group, the Italian Cooperative Soft Tissue Sarcoma Group, and the European pediatric Soft tissue sarcoma Study, Group., Paediatric Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
genetic structures, medicine.medical_treatment, Uterus, Uterine Cervical Neoplasms, Kaplan-Meier Estimate, Pediatrics, Gynecologic Surgical Procedures, 0302 clinical medicine, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Multicenter Studies as Topic, Child, Rhabdomyosarcoma, Clinical Trials as Topic, Univariate analysis, 030219 obstetrics & reproductive medicine, Soft tissue sarcoma, Remission Induction, Hematology, Perinatology and Child Health, Prognosis, Combined Modality Therapy, Progression-Free Survival, Treatment Outcome, medicine.anatomical_structure, vagina, Oncology, Child, Preschool, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Uterine Neoplasms, Vagina, Female, medicine.medical_specialty, Vaginal Neoplasms, Adolescent, Brachytherapy, brachytherapy, Urology, children, genital tract, radiotherapy, rhabdomyosarcoma, Pediatrics, Perinatology and Child Health, Article, 03 medical and health sciences, medicine, Humans, Radical surgery, business.industry, medicine.disease, Radiation therapy, business
Abstract

Background: Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed. Procedure: From 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n = 160), 2.7 for uterus corpus (n = 26), and 13.5 for uterus cervix (n = 51). Twenty-eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG). Results: Ten-year event-free (EFS) and overall survival (OS) were 74% (95% CI, 67–79%) and 92% (95% CI, 88–96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P = 0.08), there was no difference in OS (94% without RT vs. 89% with RT; P = 0.18). Local control using brachytherapy was excellent (93%). Fifty-one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery. Conclusions: About half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results